文献速递神经肿瘤

无框架立体定向活检在精准神经外科中的诊断价值、安全性与准确性

Frameless stereotactic biopsy for precision neurosurgery: diagnostic value, safety, and accuracy.
PubMed 文献 · Acta Neurochir (Wien) · 2019-03-20

胶质瘤IDH-1突变状态在108/110例(98.2%)中明确,MGMT甲基化在96例(87.3%)中明确。需手术引流的出血发生率为2.1%,无症状出血8例(5.7%),无活检相关死亡。

要点

  • 无框架立体定向活检总体诊断率为93.6%,9例未获诊断。
  • 胶质瘤IDH-1突变状态在98.2%(108/110)病例中明确。
  • 需手术引流的出血发生率为2.1%,无活检相关死亡。

核心结论

  • 无框架立体定向活检是一种安全、可行且快速的方法,可获得组织学和分子诊断。

主要发现

  • 总体诊断率为93.6%,9例未获诊断。
  • 110例胶质瘤中,IDH-1突变状态在108例(98.2%)中明确,除3例外均为野生型。
  • MGMT甲基化在96例(87.3%)中明确,60例存在甲基化。
  • 20例II-III级胶质瘤中6例检出1p/19q共缺失。
  • 需手术引流的出血发生率为2.1%,无症状出血8例(5.7%),无活检相关死亡。

关键数值与推荐

  • 胶质瘤IDH-1突变状态明确率98.2%(108/110)。
  • MGMT甲基化明确率87.3%(96/110),其中60例存在甲基化。
  • II-III级胶质瘤1p/19q共缺失检出6/20例。
  • 需手术引流的出血发生率2.1%,无症状出血5.7%(8例)。

临床怎么用

  • 无框架立体定向活检可用于不适合显微手术切除的脑病变患者,以获取组织学和分子诊断。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic biopsy is consistently employed to characterize cerebral lesions in patients who are not suitable for microsurgical resection. In the past years, technical improvement and neuroimaging advancements contributed to increase the diagnostic yield, the safety, and the application of this procedure. Currently, in addition to histological diagnosis, the molecular analysis is considered essential in the diagnostic process to properly select therapeutic and prognostic algorithms in a personalized approach. The present study reports our experience with frameless stereotactic brain biopsy in this molecular era. METHODS: One hundred forty consecutive patients treated from January 2013 to September 2018 were analyzed. Biopsies were performed using the Brainlab Varioguide® frameless stereotactic system. Patients' clinical and demographic data, the time of occupation of the operating room, the surgical time, the morbidity, and the diagnostic yield in providing a histological and molecular diagnosis were recorded and evaluated. RESULTS: The overall diagnostic yield was 93.6% with nine procedures resulting non-diagnostic. Among 110 patients with glioma, the IDH-1 mutational status was characterized in 108 cases (98.2%), resulting wild-type in all subjects but 3; MGMT methylation was characterized in 96 cases (87.3%), resulting present in 60 patients, and 1p/19q codeletion was founded in 6 of the 20 cases of grade II-III gliomas analyzed. All the specimens were apt for molecular analysis when performed. Bleeding requiring surgical drainage occurred in 2.1% of the cases; 8 (5.7%) asymptomatic hemorrhages requiring no treatment were observed. No biopsy-related mortality was recorded. Median length of hospital stay was 5 days (IQR 4-8) with mean surgical time of 60.77 min (± 23.12) and 137.44 ± 24.1 min of total occupation time of the operative room. CONCLUSIONS: Stereotactic frameless biopsy is a safe, feasible, and fast procedure to obtain a histological and molecular diagnosis.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Sciortino T, Fernandes B, Conti Nibali M, et al. Frameless stereotactic biopsy for precision neurosurgery: diagnostic value, safety, and accuracy. Acta Neurochir (Wien). 2019. PMID: 30895395. doi:10.1007/s00701-019-03873-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。